Physician profile
Dykstra Freeman
NPI 1578042727
$1,888.13
in general payments reported to CMS, 2019-2025
16 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $567 · 2023: $472 · 2024: $510 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.10 | 2022-2025 | Caplyta |
| Indivior INC. | $292.17 | 2021-2024 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $253.75 | 2021-2024 | Rexulti |
| Lundbeck LLC | $197.82 | 2021-2025 | Rexulti |
| Abbvie INC. | $178.19 | 2022-2024 | |
| Alkermes, INC. | $150.96 | 2022-2024 | Vivitrol, Vivitrol |
| Neurocrine Biosciences, INC. | $150.33 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $92.94 | 2021-2022 | |
| Axsome Therapeutics, INC. | $44.94 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $39.75 | 2025 | Cobenfy |
| Uswm, LLC | $39.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.02 | 2025 | Invega Sustenna |
| Braeburn INC. | $23.18 | 2023 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $21.16 | 2025 | Trintellix |
| Avadel Cns Pharmaceuticals, LLC | $19.55 | 2025 | Lumryz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.25 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dykstra Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.